Health · Pharma & Biotech · 2 hrs ago
Novo Nordisk to start selling Wegovy tablets in Mexico
Novo Nordisk will begin distributing Wegovy tablets in Mexico on November 11.
Mexico approved the oral version in August for adults with obesity or overweight and at least one related health condition.
The company expects the tablets to reach nearly 10,000 sales locations in the coming weeks through major private pharmacy chains.
Three in four Mexican adults have overweight or obesity, while fewer than 1% of a potential 7.5 million patients receive treatment, according to the company’s Mexico chief.
A company study found that more than 77% of adults surveyed said an oral treatment would make them more likely to seek care.
The tablet format is intended to make treatment more accessible, though its price will vary by dose and pharmacy and is expected to be close to the injectable version.
Novo Nordisk is also discussing wider access with Mexico’s government, and common side effects include nausea and vomiting that usually ease over time.
Novo Nordisk will begin distributing Wegovy tablets in Mexico on November 11, 2026.
The company expects the tablets to reach nearly 10,000 sales points in the following weeks through major private pharmacy chains.
Mexico approved oral Wegovy in August 2026, becoming the first country in Latin America to do so.
The authorization covers adults with obesity or overweight and at least one weight-related condition.
Novo Nordisk says the tablet format reflects patient preferences, and its price will vary by dose and establishment.
- Who
- Novo Nordisk is launching the tablets in Mexico.
- What
- The company will begin distributing Wegovy in tablet form.
- When
- Distribution begins November 11, 2026.
- Where
- Mexico, initially through major private pharmacy chains.
- Why
- Novo Nordisk says the tablet format responds to patient preferences and may increase access to treatment.
This story does not have two clearly opposing sides.
Mexico approved oral Wegovy, becoming the first country in Latin America to authorize it.
Novo Nordisk is scheduled to begin distributing the tablets in Mexico.
The company expects distribution to reach nearly 10,000 sales points through major private pharmacy chains.
- First Latin American approval
- Mexico, August 2026
- Distribution start
- November 11, 2026
- Expected sales points
- Nearly 10,000
- Eligible patients
- Adults with obesity or overweight and at least one weight-related condition
- Potential patient market
- About 7.5 million people
What people are saying
When we talk about oral therapy, it can significantly increase patient access to treatment
reach as many people as possible
We work closely with our different commercial partners, including the government, so that more and more patients have access to the medicine